Treatment of Non-falciparum Malaria

Efficacy and Safety of Artemether Lumefantrine Combination Therapy for the Treatment of Malaria Due to Plasmodium Ovale, Plasmodium Malariae, and Mixed Plasmodium Infections in Gabon

Patients with non-falciparum infection will be given artemether-lumefantrine for three days and will be followed up for 28 days. Besides efficacy and safety evaluations a substudy on immunology will be performed.

Inclusion Criteria:

• Male or female patients between the age of 6 months and 60 years and with a minimum of 5kg bodyweight
• Presence of uncomplicated malaria confirmed by: i)fever or history of fever in the previous 4 days, and ii)positive microscopy of P. malariae or P. ovale or mixed infection with P.falciparum with parasite density > 50-200000/μl of blood
• Written informed consent

Exclusion Criteria:

• Patients with presence of other clinical conditions requiring hospitalization
• Presence of other febrile conditions
• Presence of significant anemia, defined by hemoglobin < 7g/dl
• Known history of hypersensitivity,allergic or adverse reactions to artemether or lumefantrine
• Intake of any antimalarial or antibiotics with known antimalarial activity in the preceding 2 weeks
• Pregnant and breast feeding females